Bausch Health Companies Inc. financial data

Symbol
BHC on NYSE
Industry
Pharmaceutical Preparations
Location
2150 St. Elzear Blvd. West, Laval, Quebec, Quebec, Canada
State of incorporation
NJ
Fiscal year end
December 31
Former names
Valeant Pharmaceuticals International, Inc. (to 7/3/2018), BIOVAIL Corp (to 9/27/2010), BIOVAIL CORP INTERNATIONAL (to 4/7/2010), BIOVAIL CORPORATION INTERNATIONAL (to 1/5/2001)
Latest financial report
10-K - Q4 2024 - Feb 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 108 % -7.93%
Quick Ratio 32.4 % +0.9%
Debt-to-equity -2.27K % +21.1%
Return On Equity 19.1 %
Return On Assets -0.17 % +92.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 368M shares
Common Stock, Shares, Outstanding 368M shares +0.71%
Entity Public Float 2.13B USD -12.1%
Common Stock, Value, Issued 10.5B USD +0.64%
Weighted Average Number of Shares Outstanding, Basic 368M shares +0.85%
Weighted Average Number of Shares Outstanding, Diluted 368M shares +0.85%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 9.63B USD +9.91%
Costs and Expenses 8.08B USD +3.66%
Operating Income (Loss) 1.55B USD +60.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 167M USD
Income Tax Expense (Benefit) 239M USD +8.15%
Net Income (Loss) Attributable to Parent -46M USD +92.2%
Earnings Per Share, Basic -0.13 USD/shares +92%
Earnings Per Share, Diluted -0.13 USD/shares +92%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.18B USD +24.7%
Inventory, Net 1.6B USD +3.3%
Assets, Current 5.77B USD +3.18%
Deferred Income Tax Assets, Net 1.97B USD -6.33%
Property, Plant and Equipment, Net 1.78B USD +4.28%
Operating Lease, Right-of-Use Asset 211M USD +14.1%
Intangible Assets, Net (Excluding Goodwill) 5.55B USD -14%
Goodwill 11.1B USD -0.86%
Other Assets, Noncurrent 363M USD +18.2%
Assets 26.5B USD -3.02%
Accounts Payable, Current 656M USD -8.76%
Accrued Liabilities, Current 3.42B USD +9.22%
Liabilities, Current 6.75B USD +57%
Deferred Income Tax Liabilities, Net 128M USD -21.5%
Operating Lease, Liability, Noncurrent 165M USD +11.5%
Other Liabilities, Noncurrent 713M USD -8.12%
Liabilities 26.8B USD -2.14%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.18B USD -15.8%
Retained Earnings (Accumulated Deficit) -9.82B USD -0.47%
Stockholders' Equity Attributable to Parent -1.28B USD -25.1%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -322M USD -293%
Liabilities and Equity 26.5B USD -3.02%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 211M USD +37%
Net Cash Provided by (Used in) Financing Activities -340M USD -139%
Net Cash Provided by (Used in) Investing Activities -73M USD +6.41%
Common Stock, Shares, Issued 368M shares +0.71%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -207M USD -245%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.2B USD +24.8%
Deferred Tax Assets, Valuation Allowance 2.28B USD +1.33%
Deferred Tax Assets, Gross 4.52B USD -1.22%
Operating Lease, Liability 223M USD +6.7%
Payments to Acquire Property, Plant, and Equipment 82M USD +74.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -344M USD +17.5%
Lessee, Operating Lease, Liability, to be Paid 283M USD +12.7%
Property, Plant and Equipment, Gross 3.92B USD +3.54%
Operating Lease, Liability, Current 58M USD -4.92%
Lessee, Operating Lease, Liability, to be Paid, Year Two 53M USD -1.85%
Lessee, Operating Lease, Liability, to be Paid, Year One 74M USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +14.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 60M USD +42.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 44M USD +25.7%
Unrecognized Tax Benefits 924M USD +0.65%
Lessee, Operating Lease, Liability, to be Paid, Year Four 31M USD +6.9%
Deferred Tax Assets, Net of Valuation Allowance 2.24B USD -3.7%
Share-based Payment Arrangement, Expense 150M USD +13.6%